Wockhardt registers Q3 FY23 consolidated loss at Rs. 96 Cr
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The company has reported total income of Rs. 701 crores during the period ended December 31, 2022
The Applied Biosystems TaqPath PCR kits have been analytically- and clinically-validated for use in patient care
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
The company has announced net revenue of Rs. 639.8 crore for Q3 FY23 as compared to Rs. 562.08 crore in the corresponding period of the previous year
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights the key company collaborations in pharma to advance AI-powered drug repurposing techniques.
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
Subscribe To Our Newsletter & Stay Updated